GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Beats Estimates By $0.49 EPS

GeoVax Labs (NASDAQ:GOVX) announced its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.49, Zacks reports.

GeoVax Labs Trading Down 7.3 %

GOVX stock traded down $0.10 during mid-day trading on Thursday, hitting $1.27. 351,985 shares of the company were exchanged, compared to its average volume of 628,015. The business has a fifty day simple moving average of $1.71 and a 200-day simple moving average of $2.17. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research note on Thursday, February 27th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.